Tiziana Life Sciences PLC (LON:ADI)‘s stock had its “speculative buy” rating restated by investment analysts at Beaufort Securities in a report released on Thursday, StockTargetPrices.com reports. They presently have a GBX 0.20 ($0.00) price target on the biotechnology company’s stock. Beaufort Securities’ price objective points to a potential upside of 247.83% from the stock’s previous close.

TRADEMARK VIOLATION NOTICE: “Tiziana Life Sciences PLC (ADI) Given Speculative Buy Rating at Beaufort Securities” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/10/22/tiziana-life-sciences-plc-adi-given-speculative-buy-rating-at-beaufort-securities.html.

Tiziana Life Sciences PLC Company Profile

Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its products in clinical stage include Milciclib and Foralumab. Its products in pre-clinical stage include TZLS-101 and TZLS-214.

Stock Target Prices

Receive News & Ratings for Tiziana Life Sciences PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences PLC and related companies with MarketBeat.com's FREE daily email newsletter.